What is tubal factor infertility?
Tubal factor infertility refers to anatomical or functional impairment of the fallopian tubes that prevents fertilization or implantation. The tubes serve a critical role in natural conception: they pick up the ovulated egg, provide the environment for fertilization, and transport the developing embryo to the uterus. Damage to either tube, or particularly to both, can prevent or substantially impair natural conception.
The most common causes of tubal damage are pelvic inflammatory disease (often from prior chlamydia or gonorrhea infection), endometriosis affecting the tubes, prior tubal surgery (including elective sterilization), and pelvic adhesions from prior abdominal or pelvic surgery. Hydrosalpinx — a fluid-filled, dilated tube — is a specific subtype of tubal disease that has implications for IVF outcomes.
Tubal disease is typically evaluated by hysterosalpingogram (HSG), saline infusion sonography (SIS), or laparoscopy with chromotubation in select cases. HSG is the most common first-line test.
How common is it among IVF patients?
Tubal factor is reported as a contributing diagnosis at 445 of 458 US clinics in the most recent CDC data, with an estimated 87,858 IVF cycles annually citing tubal factor as a diagnosis.
The IVF prevalence is meaningful but lower than male factor or diminished ovarian reserve. This reflects the strong fit between IVF and tubal disease: because IVF bypasses the fallopian tubes entirely (egg retrieval is direct, fertilization happens in the lab, and embryo transfer goes directly to the uterus), IVF is often the most direct treatment for tubal disease and patients are referred from gynecologists to reproductive endocrinology specifically for IVF.
How tubal factor affects IVF outcomes
For most tubal factor patients, IVF outcomes are favorable. Because the underlying issue is anatomical and the egg-sperm-embryo pathway is preserved otherwise, fertilization rates, embryo development, and implantation rates are typically within expected ranges for the patient's age.
The notable exception is hydrosalpinx. Multiple meta-analyses have demonstrated that the presence of a hydrosalpinx — particularly one large enough to be visible on ultrasound — reduces IVF success rates substantially compared to tubal disease without hydrosalpinx. The proposed mechanisms involve embryotoxic fluid leaking back into the uterus during transfer and mechanical interference with implantation. ACOG and ASRM both note that surgical removal or interruption of the affected tube before IVF (salpingectomy or proximal tubal occlusion) restores success rates to expected levels. This is one of the few situations in fertility care where pre-IVF surgery has clearly demonstrated benefit in randomized trials.
What treatments are commonly discussed
For tubal factor infertility, the treatment options depend on the type and extent of damage:
- IVF. The most common treatment for bilateral tubal disease, severe unilateral disease, or any tubal disease where the patient prefers a high-success-per-cycle approach.
- Tubal surgery. Tubal anastomosis after sterilization ("reversal") and surgical repair of mild tubal disease are options for selected patients. Success depends heavily on the type of damage and the patient's age. Surgery does not address tubal function beyond restoring patency.
- Salpingectomy or tubal occlusion before IVF. Standard pre-IVF management for hydrosalpinx, supported by randomized trial evidence.
- Donor egg or other approaches. Considered when tubal disease is accompanied by other factors that affect outcomes, such as advanced age or DOR.
Questions to ask your fertility specialist
If tubal factor is part of your diagnosis, the following questions can help structure the conversation:
- What is the specific finding on my HSG or other imaging?
- Do I have a hydrosalpinx, and if so, do you recommend salpingectomy or tubal occlusion before IVF?
- If hydrosalpinx is present and surgery is recommended, what's the recovery timeline before we can start an IVF cycle?
- For my age and tubal findings specifically, what's your typical live birth rate?
- If I had prior tubal surgery for sterilization, are we considering reversal or going directly to IVF, and what factors are driving that recommendation?
US fertility clinics with the highest reported tubal factor cycle volume
The list below ranks US fertility clinics by estimated annual cycles citing tubal factor as a diagnosis, derived from each clinic's CDC-reported total cycle count multiplied by the percentage of cycles citing this diagnosis. Volume is a signal that a clinic regularly treats this diagnosis. It is not a measure of success rate or quality. CDC does not publish per-diagnosis success rates at the clinic level, so a "best clinic for tubal factor" cannot be derived from this dataset alone.
How we computed these numbers
The clinic-level numbers on this page come from the CDC's National ART Surveillance System (NASS), specifically the 2022 ART Surveillance Report, which is the most recent dataset available. CDC publishes these reports on a two-year lag.
Estimated annual cycles for this diagnosis are computed by multiplying each clinic's total reported cycles by the percentage of cycles in which tubal factor was cited as a diagnosis. The CDC reports these percentages but does not publish absolute cycle counts per diagnosis, so the figures here are estimates.
A single IVF cycle can have multiple diagnoses recorded. A patient with both male factor and diminished ovarian reserve would have both diagnoses counted, which is why the percentages reported by clinics often sum to more than 100%. The "share of all CDC IVF cycles" stat above is therefore an approximation of how often this diagnosis appears in any cycle's record, not a percentage of cycles where it is the sole cause.
Editorial content on this page was last reviewed on April 30, 2026. We aim to update each diagnosis page when major guidelines from ASRM, ACOG, AUA, the Endocrine Society, or related professional bodies are revised.
Sources
- American College of Obstetricians and Gynecologists. Infertility Workup for the Women's Health Specialist. ACOG Committee Opinion No. 781.
- Practice Committee of the American Society for Reproductive Medicine. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion.
- Centers for Disease Control and Prevention. 2022 Assisted Reproductive Technology National Summary Report.